Payment overview · 2025
General Payments
$3,911.29
184 reported records · 40 companies
Healthcare provider profile · identity verified
Bernard Aron Michlin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1861492738
Verified facts
What the public records show
CMS Open Payments records show Bernard Aron Michlin, M.D. received $3,911.29 in general payments during 2025 across 184 reported records.
Vanda Pharmaceuticals Inc. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 61 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Briviact, Caplyta, Eliquis, Fanapt, Farxiga, Gemtesa, Ingrezza, Jardiance, Kerendia, Nurtec Odt, Ozempic, Qulipta, Rexulti, Rybelsus, Valtoco, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 545 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Gemtesa by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Briviact by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $533.61 | 13.6% | 16 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $309.31 | 7.9% | 22 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $261.42 | 6.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.80 | 6.0% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $215.77 | 5.5% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $204.71 | 5.2% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $193.45 | 5.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.25 | 3.7% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.05 | 3.7% | 8 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$139.80 | 3.6% | 16 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $132.31 | 3.4% | 4 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $117.60 | 3.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.63 | 2.5% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $94.26 | 2.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $92.42 | 2.4% | 4 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.11 | 2.3% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $79.69 | 2.0% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.01 | 1.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $61.36 | 1.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.57 | 1.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.39 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.98 | 1.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $45.02 | 1.1% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $44.88 | 1.1% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 1.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $40.58 | 1.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.11 | 1.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.01 | 1.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.54 | 0.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.94 | 0.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.55 | 0.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.00 | 0.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $24.39 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.82 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.65 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.74 | 0.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.31 | 0.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.63 | 0.5% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.16 | 0.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.96 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,868.79 | 183 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $533.61 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $261.42 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $215.77 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $204.71 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $193.45 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.79 | 11 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $142.96 | 9 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $139.80 | 16 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $132.31 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $117.79 | 10 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $117.60 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.72 | 11 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $99.63 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $99.63 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $99.37 | 5 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $91.11 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $88.44 | 9 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $79.69 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $75.81 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $70.01 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $61.36 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.11 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.81 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $55.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $54.57 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $48.56 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| DRIZALMA SPRINKLE Normalized: drizalma sprinkle |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 26 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 408 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 545 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 108 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 306 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
263 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
51 | 29 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
99 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
545 | 79 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
408 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
229 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
239 | 37 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
306 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
408 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
108 | 12 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1448 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1367 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 931 | 155 |
| Lisinopril | Lisinopril | 849 | 156 |
| Farxiga | Dapagliflozin Propanediol | 545 | 79 |
| Gabapentin | Gabapentin | 517 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 515 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 501 | 80 |
| Metformin Hcl | Metformin Hcl | 497 | 69 |
| Losartan Potassium | Losartan Potassium | 456 | 99 |
| Mirtazapine | Mirtazapine | 442 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 98 |
| Trazodone Hcl | Trazodone Hcl | 433 | 79 |
| Eliquis | Apixaban | 408 | 51 |
| Omeprazole | Omeprazole | 383 | 66 |
| Divalproex Sodium | Divalproex Sodium | 377 | 54 |
| Famotidine | Famotidine | 363 | 59 |
| Methenamine Hippurate | Methenamine Hippurate | 344 | 57 |
| Olanzapine | Olanzapine | 337 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 328 | 61 |
| Ozempic | Semaglutide | 306 | 57 |
| Risperidone | Risperidone | 293 | 48 |
| Lactulose | Lactulose | 278 | 48 |
| Finasteride | Finasteride | 273 | 42 |
| Benztropine Mesylate | Benztropine Mesylate | 269 | 37 |
| Linzess | Linaclotide | 263 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 49 |
| Carvedilol | Carvedilol | 243 | 48 |
| Donepezil Hcl | Donepezil Hcl | 239 | 26 |
| Trulicity | Dulaglutide | 239 | 37 |
| Buspirone Hcl | Buspirone Hcl | 234 | 47 |
| Dapagliflozin | Dapagliflozin Propanediol | 234 | 40 |
| Levetiracetam | Levetiracetam | 232 | 33 |
| Xarelto | Rivaroxaban | 229 | 21 |
| Jardiance | Empagliflozin | 212 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 46 |
| Alendronate Sodium | Alendronate Sodium | 207 | 29 |
| Memantine Hcl | Memantine Hcl | 192 | 23 |
| Lamotrigine | Lamotrigine | 187 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 180 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 38 |
| Clonazepam | Clonazepam | 176 | 30 |
| Levocarnitine | Levocarnitine | 174 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 174 | 37 |
| Simvastatin | Simvastatin | 174 | 29 |
| Clozapine | Clozapine | 168 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 44 |
| Lacosamide | Lacosamide | 148 | 29 |
| Potassium Chloride | Potassium Chloride | 143 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 140 | 29 |
| Sertraline Hcl | Sertraline Hcl | 135 | 27 |
| Propranolol Hcl | Propranolol Hcl | 134 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 31 |
| Divalproex Sodium Er | Divalproex Sodium | 122 | 17 |
| Topiramate | Topiramate | 122 | 12 |
| Spironolactone | Spironolactone | 121 | 31 |
| Ibuprofen | Ibuprofen | 120 | 58 |
| Clonidine Hcl | Clonidine Hcl | 112 | 31 |
| Furosemide | Furosemide | 111 | 37 |
| Gemtesa | Vibegron | 108 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 107 | 26 |
| Latanoprost | Latanoprost | 104 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 17 |
| Carbamazepine | Carbamazepine | 100 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 43 |
| Amantadine | Amantadine Hcl | 99 | suppressed |
| Myrbetriq | Mirabegron | 99 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 19 |
| Montelukast Sodium | Montelukast Sodium | 96 | 15 |
| Haloperidol | Haloperidol | 95 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 19 |
| Aripiprazole | Aripiprazole | 85 | 20 |
| Buprenorphine Hcl | Buprenorphine Hcl | 85 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 85 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 85 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 81 | suppressed |
| Lubiprostone | Lubiprostone | 81 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 81 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Lorazepam | Lorazepam | 80 | 30 |
| Digoxin | Digoxin | 75 | 12 |
| Fanapt | Iloperidone | 75 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 75 | 16 |
| Lurasidone Hcl | Lurasidone Hcl | 75 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 74 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 74 | 11 |
| Olanzapine Odt | Olanzapine | 73 | 13 |
| Atenolol | Atenolol | 72 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 72 | suppressed |
| Valsartan | Valsartan | 72 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 11 |
| Ketoconazole | Ketoconazole | 69 | 37 |
| Nystatin | Nystatin | 69 | 35 |
| Ingrezza | Valbenazine Tosylate | 68 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 68 | suppressed |
| Alprazolam | Alprazolam | 67 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 39 |
| Gemfibrozil | Gemfibrozil | 64 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 12 |
| Baclofen | Baclofen | 60 | 13 |
| Bupropion Xl | Bupropion Hcl | 60 | 11 |
| Meloxicam | Meloxicam | 60 | 11 |
| Oxcarbazepine | Oxcarbazepine | 60 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 42 |
| Midodrine Hcl | Midodrine Hcl | 57 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Hydrocortisone | Hydrocortisone | 54 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 14 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Lansoprazole | Lansoprazole | 52 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 17 |
| Entresto | Sacubitril/Valsartan | 51 | 14 |
| Enulose | Lactulose | 51 | 12 |
| Kerendia | Finerenone | 51 | suppressed |
| Prolia | Denosumab | 51 | 29 |
| Clonidine | Clonidine | 50 | 13 |
| Allopurinol | Allopurinol | 49 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 49 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 49 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 14 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 47 | suppressed |
| Rexulti | Brexpiprazole | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 27 |
| Vraylar | Cariprazine Hcl | 44 | suppressed |
| Clotrimazole | Clotrimazole | 42 | 13 |
| Tramadol Hcl | Tramadol Hcl | 42 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Carbamazepine Er | Carbamazepine | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | suppressed |
| Prednisone | Prednisone | 41 | 16 |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 40 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 37 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 37 | suppressed |
| Permethrin | Permethrin | 37 | 22 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Clozapine Odt | Clozapine | 36 | suppressed |
| Dutasteride | Dutasteride | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 35 | suppressed |
| Methimazole | Methimazole | 35 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Methadone Hcl | Methadone Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Diazepam | Diazepam | 32 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 32 | 16 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 13 |
| Santyl | Collagenase Clostridium Hist. | 28 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Calcitriol | Calcitriol | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Caplyta | Lumateperone Tosylate | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Dupixent Pen | Dupilumab | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Nystop | Nystatin | 19 | 12 |
| Testosterone | Testosterone | 19 | suppressed |
| Valproic Acid | Valproic Acid | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Motegrity | Prucalopride Succinate | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Briviact | Brivaracetam | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ivermectin | Ivermectin | 13 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Valtoco | Diazepam | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,911.29 · 184 records | Vanda Pharmaceuticals Inc. | AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, AVYCAZ, Auvelity, BREZTRI, Briviact, CAPLYTA, CERDELGA, CEREZYME, COBENFY, CREON, Cologuard Collection Kit, DALVANCE, DRIZALMA SPRINKLE, DUPIXENT, ELIQUIS, EMBLAVEO, FABRAZYME, FANAPT, FARXIGA, Fintepla, GEMTESA, IBSRELA, INGREZZA, INJECTAFER, JARDIANCE, JATENZO, KISUNLA, KRYSTEXXA, Kerendia, MITRACLIP, NURTEC ODT, Natroba, Nayzilam, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SUBLOCADE, Spinosad, TEFLARO, Tlando, UBRELVY, UPLIZNA, UZEDY, VALTOCO, VRAYLAR, VYKAT XR, Veozah, WAKIX, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP | 38 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error